Rate My Professor Carl Kirkpatrick

Professor Kirkpatrick's research centers on population pharmacokinetic and pharmacodynamic modelling to optimize pharmacotherapy, with a focus on antibacterial agents, dosing in renal dysfunction, obesity, drugs in breast milk, quality use of medicines, pharmacogenomics, anti-infectives, and mRNA therapeutics. His work has an h-index of 56 and over 12,416 citations. Key publications include 'Monte Carlo simulations: Maximizing antibiotic pharmacokinetic/pharmacodynamic target attainment using a population pharmacokinetic model of piperacillin and tazobactam in critically ill patients' (2011), 'Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients' (2007), 'AI for NONMEM Coding in Pharmacometrics Research and Education: Shortcut or Pitfall?' (2025), and 'Clinical and Quantitative Pharmacology Considerations of mRNA Therapeutics and Vaccine Development: Bridging Translational and Platform Gaps for Enhanced Decision Making' (2025). He has supervised more than 22 PhD students, obtained continuous NHMRC funding, and held leadership positions such as President of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT), Chair of the World Congress of Basic and Clinical Pharmacology 2026, and member of the Advisory Committee on Prescription Medicines Pharmaceutical Subcommittee. His awards include the 2025 ASCEPT Fellowship, 2024 Fellowship of the British Pharmacological Society, and 2024 Australian Award for University Teaching.